In cooperation with shareholder Prescience Point Capital Management LLC, MiMedx (OTC:MDXG) plans to rejigger its board of directors, adding six new members including new CEO Timothy Wright and three Prescience nominees. Sarepta Therapeutics Chairman M. Kathleen Behrens Wilsey, Ph.D. will chair the MiMedx board.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.